抗生素
细菌
抗菌剂
利奈唑啉
化学
抗生素耐药性
药品
药理学
计算生物学
微生物学
生物
生物化学
遗传学
万古霉素
金黄色葡萄球菌
作者
Maxwell Ampomah‐Wireko,Shengcong Chen,Ruirui Li,Chen Gao,Meng Wang,Ye Qu,Hongtao Kong,Lauraine Nininahazwe,En Zhang
标识
DOI:10.1016/j.ejmech.2024.116326
摘要
Bacterial infections cause a variety of life-threatening diseases, and the continuous evolution of drug-resistant bacteria poses an increasing threat to current antimicrobial regimens. Gram-positive bacteria (GPB) have a wide range of genetic capabilities that allow them to adapt to and develop resistance to practically all existing antibiotics. Oxazolidinones, a class of potent bacterial protein synthesis inhibitors with a unique mechanism of action involving inhibition of bacterial ribosomal translation, has emerged as the antibiotics of choice for the treatment of drug-resistant GPB infections. In this review, we discussed the oxazolidinone antibiotics that are currently on the market and in clinical development, as well as an updated synopsis of current advances on their analogues, with an emphasis on innovative strategies for structural optimization of linezolid, structure-activity relationship (SAR), and safety properties. We also discussed recent efforts aimed at extending the activity of oxazolidinones to gram-negative bacteria (GNB), antitumor, and coagulation factor Xa. Oxazolidinone antibiotics can accumulate in GNB by a conjugation to siderophore-mediated β-lactamase-triggered release, making them effective against GNB.
科研通智能强力驱动
Strongly Powered by AbleSci AI